Bristol Myers Squibb partnered with Faro Health to use AI-driven structured design for clinical trial protocol development, according to company statements. The multiyear effort is intended to convert narrative protocol elements—such as objectives, endpoints, and schedules—into structured digital assets that can be used across drafting, validation, optimization, and compliance workflows. BMS said the change reflects a shift away from document-based development processes, with Faro describing its platform as a “system of record” for protocol structure. The platform’s validation approach includes consistency checks and benchmarking against frameworks such as the Tufts Center for the Study of Drug Development. For biotech operators, the practical implication is likely faster protocol iterations and reduced rework, especially for complex studies where scheduling and site burden planning are often time-consuming.